Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most high-level safety/efficacy and MOA statements align with the provided COSENTYX label excerpts, but several specific claims are either not supported with the necessary detail (pediatric efficacy percentages/12-week PASI) or overreach beyond what the supplied excerpts explicitly state (cardiovascular events, autoimmune triggers beyond hypersensitivity/immune reactions, malignancy, and expanded monitoring elements such as routine liver/kidney/blood counts).
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported by Section 1.1 (plaque psoriasis in adults and pediatric patients ≥6), Section 1.2 (psoriatic arthritis in adults and pediatric patients ≥2), and Section 1.3 (ankylosing spondylitis in adults and pediatric patients ≥12).
Cosentyx works by blocking interleukin-17A (IL-17A).
Supported by Section 12.1: secukinumab selectively binds IL-17A and inhibits its interaction with the IL-17 receptor (IL-17A antagonist).
Cosentyx use is associated with an increased risk of infections, including serious infections such as tuberculosis and fungal infections.
Supported by Section 5.1 (increased risk of infections, including postmarketing serious opportunistic and fatal infections; serious bacterial/viral/fungal opportunistic infections reported) and Section 5.3 (evaluate for active/latent TB; avoid in active TB; initiate latent TB treatment prior to COSENTYX).
Some children may experience allergic reactions with Cosentyx, including anaphylaxis.
Supported by Section 5.2 (serious hypersensitivity including anaphylaxis reported) and Section 4 contraindication notes anaphylaxis/angioedema reported; pediatric-specific frequency is not provided in excerpts.
Common side effects of Cosentyx in children include injection site reactions, headache, fatigue, and upper respiratory tract infections.
Not explicitly supported by the provided excerpts (Section 6.1-6.2 excerpts are general and do not list these specific common pediatric side effects).
Unsupported Statements
In children, Cosentyx is shown to be effective in reducing symptoms of psoriasis and psoriatic arthritis.
The excerpts confirm pediatric indications (Section 1.1 and 1.2) and that clinical studies exist by indication, but no pediatric efficacy outcomes in the provided label excerpts explicitly describe 'reducing symptoms' for psoriasis and psoriatic arthritis.
In a study of children with moderate to severe psoriasis, 75% achieved a 75% reduction in PASI scores after 12 weeks of Cosentyx treatment.
No PASI 75 value, percentage, or 12-week pediatric outcome is present in the provided label excerpts.
There may be a potential increased risk of malignancy with Cosentyx, including lymphoma and skin cancer.
The provided excerpts do not mention malignancy/lymphoma/skin cancer risk.
Cosentyx may trigger autoimmune disorders, such as lupus or rheumatoid arthritis.
The provided excerpts do not mention triggering autoimmune disorders such as lupus or rheumatoid arthritis.
There is a potential increased risk of cardiovascular events with Cosentyx, including heart attacks and strokes.
The provided excerpts do not mention cardiovascular events (MI/stroke) risk.
Monitoring children on Cosentyx includes regular blood tests to monitor liver function, kidney function, and blood counts.
The provided excerpts include TB evaluation and immunization guidance (Section 2.1, 5.3, 5.7) but do not specify routine LFTs, renal function tests, or blood count monitoring.
Monitoring children on Cosentyx includes autoimmune disorder screening to detect signs of autoimmune disorders, such as lupus or rheumatoid arthritis.
The provided excerpts do not describe screening for lupus/rheumatoid arthritis or autoimmune disorder monitoring.
Common side effects of Cosentyx in children include injection site reactions, headache, fatigue, and upper respiratory tract infections.
The provided excerpts do not list these specific common pediatric adverse reactions.
Contradictions
Important Omissions
For infection risk management: the label excerpt specifies TB evaluation (active/latent) and initiation of latent TB treatment before starting and monitoring during/after; it does not support broad routine infection screening wording as stated.
Importance:
Moderate
Immunization precautions: label excerpt includes completing age-appropriate vaccinations prior to initiating therapy and avoiding live vaccines during treatment; the response did not mention this.
Importance:
Moderate
IBD-related warning: label excerpt includes inflammatory bowel disease (IBD) exacerbations/new onset with caution/monitoring; the response did not mention this.
Importance:
Moderate
Administration discontinuation guidance: the response recommends consulting a child's doctor before stopping due to flare-up; the provided excerpts do not describe a 'sudden withdrawal' flare-up risk or any stopping guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overstated or unsupported claims (malignancy risk, autoimmune triggers, cardiovascular risk) and potentially inaccurate monitoring instructions (routine liver/kidney/blood counts and autoimmune screening) could mislead clinical monitoring decisions. Infection risk and hypersensitivity statements are broadly consistent with the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several specific claims are not supported by the provided label excerpts (pediatric PASI 75/12-week result; malignancy/autoimmune/cardiovascular risks; and detailed monitoring labs/autoimmune screening; also pediatric common side-effect list).
Suggested Improvement
Limit statements to label-excerpt-supported claims (indications by section, IL-17A mechanism, infection risk and TB evaluation approach, hypersensitivity including anaphylaxis). Remove unsupported disease-risk and monitoring details not present in the provided excerpts, and cite immunization and IBD precautions if included.